Takeda terminates collaboration; Finch regains full rights to IBD candidates FIN-524 and FIN-525

Finch Therapeutics Group, Inc.

Takeda terminated collaboration for convenience effective Nov 17, 2022; Finch regains worldwide rights to FIN-524 and FIN-525.
Finch received over $44M total from Takeda ($10M upfront, $4M milestones, over $30M R&D reimbursement).
Finch will receive royalty-free license to all data and intellectual property generated during the collaboration.
Finch is conducting a portfolio review and assessing financial and strategic impact of the termination.
No new revenue or guidance provided; future development path for IBD candidates uncertain.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.